We have located links that may give you full text access.
Comparison of cementless total hip arthroplasty survivorship between metal-on-highly cross-linked polyethylene and ceramic on ceramic bearings: A case control study with a 5-9-year follow-up.
Orthopaedics & Traumatology, Surgery & Research : OTSR 2018 September
BACKGROUND: Currently, there is a lack of evidence on the medium-term follow-up of cementless total hip arthroplasty (THA) using metal-on-highly cross-linked polyethylene bearing (MoXPE), ceramic on ceramic bearing (CoC) at more than 5 years follow-up. Therefore, we performed a case control study to: compare the incidence rate of osteolysis; compare the longevity for both types of THAs, and to evaluate the wear rate of MoXPE THAs.
HYPOTHESIS: CoC THAs will have a lower rate of osteolysis and better longevity than MoXPE THAs.
PATIENTS AND METHODS: We performed a retrospective analysis of 77 MoXPE (68 women, 9 men) and 105 CoC (85 women, 20 men) THAs, with an average patient age at the time of surgery of 64.7 years (range, 27 to 76 years). The cohorts were matched according to sex, body mass index, or diagnosis of hip joint disease. Clinical and radiologic measurements were analyzed at a mean follow-up of 6.7 years (range, 5-9 years).
RESULTS: There were no between-group differences with regard to the Harris hip score (87.0 [64.0-98.0] and 89.9 [70.0-100.0] for the MoXPE and CoC group, respectively) and the incidence rate of osteolysis (2.6% and 1.9%, respectively). Revision was required for 1 case for each THA type. The Kaplan-Meier survival at 8 years, using implant loosening or revision as the end-point of analysis, was 96.1% (95% confidence interval [CI], 90.0-99.3) for the MoXPE group and 98.9% (95% CI, 92.2-99.8) for the CoC group (p=0.189). The mean annual liner wear rate was 0.0160mm/year (range, 0.0050 to 0.0390mm/year) for the MoXPE THAs.
DISCUSSION: There was no difference between CoC and MoXPE THAs in the incidence of osteolysis or in survival rate at 8 years post-surgery. Excellent clinical and radiological outcomes were obtained for both types of bearings.
LEVEL OF EVIDENCE: III, Case control study, case control retrospective design.
HYPOTHESIS: CoC THAs will have a lower rate of osteolysis and better longevity than MoXPE THAs.
PATIENTS AND METHODS: We performed a retrospective analysis of 77 MoXPE (68 women, 9 men) and 105 CoC (85 women, 20 men) THAs, with an average patient age at the time of surgery of 64.7 years (range, 27 to 76 years). The cohorts were matched according to sex, body mass index, or diagnosis of hip joint disease. Clinical and radiologic measurements were analyzed at a mean follow-up of 6.7 years (range, 5-9 years).
RESULTS: There were no between-group differences with regard to the Harris hip score (87.0 [64.0-98.0] and 89.9 [70.0-100.0] for the MoXPE and CoC group, respectively) and the incidence rate of osteolysis (2.6% and 1.9%, respectively). Revision was required for 1 case for each THA type. The Kaplan-Meier survival at 8 years, using implant loosening or revision as the end-point of analysis, was 96.1% (95% confidence interval [CI], 90.0-99.3) for the MoXPE group and 98.9% (95% CI, 92.2-99.8) for the CoC group (p=0.189). The mean annual liner wear rate was 0.0160mm/year (range, 0.0050 to 0.0390mm/year) for the MoXPE THAs.
DISCUSSION: There was no difference between CoC and MoXPE THAs in the incidence of osteolysis or in survival rate at 8 years post-surgery. Excellent clinical and radiological outcomes were obtained for both types of bearings.
LEVEL OF EVIDENCE: III, Case control study, case control retrospective design.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app